TrialLeukemia & lymphoma2015

A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.

Thomas J Kipps et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.